EGFR and neoplasm: In this context, the novel findings of the present study demonstrate that EGFR mutant NSCLC cancer cells stimulated with IL-1β may release sEVs containing factors that promote epithelial–mesenchymal transition (EMT) in recipient cells, the downregulation of anti-tumor immune response, and the survival of circulating metastatic cells.